Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_31_2313 - 2 Year Quality of Life Follow up Following Palladium-103 Line Source for Prostate Brachytherapy Implants

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

2 Year Quality of Life Follow up Following Palladium-103 Line Source for Prostate Brachytherapy Implants
K. Perez1, B. J. Moran Jr2, B. R. Prestidge3, J. Kaminetsky4, and R. G. Stock5; 1CivaTech Oncology, Durham, NC, 2Prostate Cancer Foundation of Chicago, Westmont, IL, 3DePaul Medical Center, Bon Secours Cancer Institute, Norfolk, VA, 4Manhattan Medical Research, New York City, NY, 5Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Purpose/Objective(s): To assess the quality of life (QOL) following the implant of a polymer encapsulated Pd-103 source with a unique linear radioactive distribution intended to provide a useful refinement on prostate brachytherapy. Prostate brachytherapy is known to successfully treat prostate cancer with minimal side effects to patients. Urinary, rectal and sexual function toxicities are reported with standard questionnaires to assess QOL in this registry study.

Materials/Methods: 37 subjects with prostate cancer were implanted with the Pd-103 line source. Prostate specific antigen (PSA) was recorded before implant and in 6 month intervals following implant. Patients were asked to respond to International Prostate Symptom Score (IPSS), Rectal Function Assessment Score (RFAS), and International Index of Erectile Function (IIEF) questionnaires. Questionnaires were administered before implant, one month after implant, and at 6 month intervals following implant. PSA and responses to questionnaires have been collected for up to 24 months for some patients. Patients were not excluded based on pre-implant QOL function.

Results: The average PSA prior to implant and at 6 months following implant were 7.7 and 1.2, respectively. A total of 37 patients responded to the questionnaires prior to linear Pd-103 implant. Very mild urinary symptoms were reported following implant, including mild increase in frequency and urgency. These symptoms resolved prior to 6 month follow up. The average baseline IPSS for all patients is 9.1. The average post implant IPSS change from baseline was 11.3, 3, 1.9, 3.1 and 0.3 for months 1, 6, 12, 18 and 24, respectively. The IPSS reported for Pd-103 linear sources indicate that return to baseline may occur more rapidly than with traditional seeds. No adverse events related to rectal toxicity were reported. The average change from baseline RFAS and IIEF were 2 and 5, respectively, at one month post implant and returned to baseline by 6 months. No statistically significant changes from baseline in the RFAS or IIEF over the 2 year follow up period.

Conclusion: Patients tolerate Pd-103 line source brachytherapy with minimal side effects. Immediate symptoms from the procedure resolve quickly and patients routinely return to baseline function.

Author Disclosure: K. Perez: Stock Options; CivaTech Oncology. Vice President Clinical Programs; CivaTech Oncology. B.J. Moran: None. B.R. Prestidge: Research Grant; CivaTech Oncology. Vice Chair; ASTRO NRC Committee. J. Kaminetsky: Research Grant; CivaTech Oncology. R.G. Stock: Honoraria; BARD.

Send Email for Kristy Perez


Assets

SU_31_2313 - 2 Year Quality of Life Follow up Following Palladium-103 Line Source for Prostate Brachytherapy Implants



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for 2 Year Quality of Life Follow up Following Palladium-103 Line Source for Prostate Brachytherapy Implants